ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/FGFR3
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/FGFR3
7
trial(s) found.
NCT05727176
Advanced
Phase 2
Recruiting
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (
FOENIX-CCA4
)
pan-FGFR inhibitor,irreversible
+ FGFR3 inhibitor
Cholangiocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05614739
Advanced
Phase 1
Recruiting
FORAGER-1
: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations
FGFR3 inhibitor
Bladder cancer
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
NCT05544552
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (
SURF301
)
FGFR3 inhibitor
Bladder cancer
Cancer
Carcinoma
FGFR3:alteration
Solid tumour
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ FGFR3 inhibitor
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ FGFR3 inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000532505
Radonc
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ FGFR3 inhibitor
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12616001187437
Advanced
Phase 2
Not recruiting
Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing. (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,first generation
ALK inhibitor,second generation
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,first generation
BCR-ABL1 inhibitor,second generation
Bortezomib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Cabozantinib
Ceritinib
Crizotinib
Dasatinib
EGFR inhibitor
EGFR inhibitor,first generation
EGFR inhibitor,type II
ERBB2 inhibitor
ERBB2 inhibitor,first generation
Erlotinib
Everolimus
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
FLT3 inhibitor
Gefitinib
HDAC inhibitor
IGF1R inhibitor
Imatinib
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,ATP-competitive
KIT inhibitor,first generation
Lapatinib
MEK inhibitor
MET inhibitor
MET inhibitor,type 1
MET inhibitor,type 2
Nilotinib
Olaparib
PARP inhibitor
PDGFRA inhibitor
PDGFR inhibitor
Palbociclib
Pazopanib
RAF inhibitor
RET inhibitor
ROS1 inhibitor
Ramucirumab
Regorafenib
SRC inhibitor
Sorafenib
Sunitinib
Trametinib
VEGFR2 inhibitor
VEGFR inhibitor
Vorinostat
YES1 inhibitor
anti-VEGFR2 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,AXL-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,ERBB2-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,FLT3-targeting
cancer therapy,HDAC-targeting
cancer therapy,IGF1R-targeting
cancer therapy,KIT-targeting
cancer therapy,MEK-targeting
cancer therapy,MET-targeting
cancer therapy,PARP-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,RAF-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,VEGFR2-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,proteasome-targeting
immuno-oncology therapy,VEGFR2-targeting
mTORC1 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
proteasome inhibitor
+ FGFR3 inhibitor
Melanoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Not recruiting (1)
Recruitment Country and State
NSW (6)
VIC (4)
WA (4)
QLD (3)
NZ (1)
SA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (4)
Radonc (3)
Cancer Therapy Class
FGFR3
100%
FGFR1
71%
FGFR1/2/3
71%
FGFR2
71%
FGFR4
71%
KIT
57%
PDGFR
57%
RET
57%
VEGFR
57%
mTOR
29%
mTORC1
29%
Nectin4
14%
PD-1
14%
PD-1/PD-L1
14%
ATM
14%
PI3K
14%
PI3K alpha
14%
PI3K delta
14%
mTORC2
14%
ALK
14%
AXL
14%
BCR-ABL1
14%
CDK4
14%
CDK6
14%
CRAF
14%
EGFR
14%
ERBB2
14%
FLT3
14%
HDAC
14%
IGF1R
14%
MEK
14%
MET
14%
PARP
14%
PDGFRA
14%
RAF
14%
ROS1
14%
SRC
14%
VEGFR2
14%
YES1
14%
proteasome
14%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
4215 - Southport - Tasman Oncology (1)
6009 - Nedlands - Linear Clinical Research (1)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
Cancer Type
Cancer
Solid tumour
Bladder cancer
Urogenital cancer
Sarcoma
Biliary tract cancer
Cholangiocarcinoma
Gastrointestinal cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Carcinoma
FGFR3:alteration
Urothelial carcinoma
Rhabdomyosarcoma
Soft tissue sarcoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy